PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Am Acad Dermatol. Author manuscript; available in PMC 2012 December 1.
Published in final edited form as:
PMCID: PMC3184340
NIHMSID: NIHMS304088

Supplement Use and Risk of Cutaneous Squamous Cell Carcinoma

Maryam M. Asgari, MD MPH,1,2 Mary-Margaret Chren, MD,2,3 E. Margaret Warton, MPH,1 Gary D. Friedman, MD MS,1,4 and Emily White, PhD5,6

Abstract

BACKGROUND

Laboratory and epidemiologic studies suggest that certain dietary supplements may alter risk of cutaneous squamous cell carcinoma (SCC).

OBJECTIVE

To examine the association between supplement use and SCC risk.

METHODS

Cases (n= 415) were defined as Kaiser Permanente Northern California (KPNC) members with a pathology-verified SCC in 2004 and controls (n=415) were age, gender, and race-matched members with no previous history of skin cancer. Supplement use and SCC risk factors were ascertained by questionnaire. Associations of SCC with use of multivitamins, vitamins A, C, D and E, and grape seed extract were estimated as odds ratios (OR) and 95% confidence intervals (CI) using conditional logistic regression. Models were adjusted for SCC risk factors and other supplement use.

RESULTS

Grape seed extract users had a significantly decreased risk of cutaneous SCC (adjusted OR = 0.26, CI: 0.08-0.89, p=0.031). Multivitamin use was associated with a borderline significant reduction in SCC risk (adjusted OR = 0.71, CI: 0.51-1.00, p= 0.049). Use of vitamins A, C, D, and E was not associated with SCC risk.

LIMITATIONS

The data may be prone to recall and selection bias due to the case-control design. No information was obtained on dose or duration of supplement use.

CONCLUSIONS

Use of grape seed extract may be associated with a decreased risk of cutaneous SCC. The other supplements included in our study did not reveal clear associations with SCC risk.

Keywords: Antioxidant, Skin cancer, Squamous Cell Carcinoma, Supplement, Vitamin, Epidemiology

INTRODUCTION

Vitamins, including vitamins A (retinol), C (ascorbic acid), D (califerol), and vitamin E (tocepherol) have been shown in both in vitro and in vivo studies to prevent oxidative damage to keratinocytes,1,2 suggesting a putative role in the chemoprevention of keratinocyte-derrived carcinomas, including squamous cell carcinoma (SCC).3,4 Certain herbal supplements, including polypodium leucotomos, derived from a tropical South American fern, and grape seed extract, derived from the seeds of grapes (Vitis vinifera), have also been associated with photoprotective effects5,6 as well as a reduction in cutaneous carcinogensis in laboratory settings.7,8,9-11 Grape seed extract (GSE) is a rich source of proanthocyanidins and polyphenolic antioxidants which are potent free radical scavengers12,13 and are postulated to mediate their chemopreventive effects by upregulating Bcl-2 and IL-12, and down regulating 1L-10 production, c-myc, p53, and the expression of NF-kappa B-targeted genes.6,12 GSE has been shown to have potent anticarcinogenic activity in keratinocytes,9 in skin carcinoma cell lines, 10, and in mouse models.11 Although laboratory evidence supports the hypothesis that boosting endogenous antioxidants through oral intake can reduce cutaneous carcinogenesis,14-16 epidemiologic studies have failed to show a consistent chemoprotective effect of oral supplement use and risk of cutaneous SCC.17,18 In fact, a recently published randomized controlled trial of nutritionnally appropriate doses of antioxidant supplements implicated a harmful effect of supplements on overall skin cancer risk.19

We conducted a case-control study to investigate whether supplement use is associated with SCC risk using the Kaiser Permanente Northern California (KPNC) population. KPNC electronic records include a comprehensive pathology database through which cutaneous SCCs can be accurately identified. We used a self-administered questionnaire to ascertain SCC risk factors and exposure to 7 vitamin and herbal supplements over the 10 years preceding the diagnosis date. These supplements were selected a priori based on data in the literature suggesting an association between their use and SCC risk.4,6,20,21 Our aim was to test whether supplements that have been previously shown to be associated with reductions in photo-oxidative damage in laboratory studies were associated with a reduction in SCC risk.

METHODS

Study Population

Data were derived from a case-control study designed to examine the association between non-steroidal anti-inflammatory drug (NSAID) use and SCC risk.22 The study population consisted of a random representative sample of 415 KPNC members (ages 43 to 85) with a pathology-confirmed squamous cell carcinoma diagnosed in 2004 and 415 control subjects matched to cases by year of birth, sex and self-reported race.

Subjects were excluded if (1) their spoken language was not English (to maximize questionnaire comprehension), (2) they had a membership gap > 4 months between January 1995 to December 2004, (3) they had a diagnosis of dementia within 10 years prior to SCC diagnosis (4) they were age > 85 years, or (5) they had a history of organ transplantation. Each participant was contacted by mail, informed about the overarching goal of the study (“to identify factors that can cause and help prevent skin cancer”), and after informed consent was obtained, asked to complete a self-administered questionnaire inquiring about demographics, skin cancer risk factors, health habits, and exposure to select drugs (NSAIDs) and supplements. This study was approved by the Kaiser Foundation Research Institute Institutional Review Board (CN-05MAsga-01-H, approved January 10, 2006) and was conducted according to the Declaration of Helsinki principles.

From a pool of 1052 eligible cases, 581 were randomly selected by primary care provider, 81% (n=472) of whom completed the questionnaire. Of those 472 participants, 422 were able to be matched with a responding control. Control subjects were drawn from respondents to the 2005 Member Health Survey (MHS), a general health survey mailed to a random sample of KPNC adult members. We chose MHS participants because this survey asked questions on self-identified race and history of prior cancer. Of the MHS respondents who reported no history of cancer, potential controls were matched by year of birth ±1 year, sex and race to cases (n=1801). We had a 57% response rate for the 736 controls contacted, achieving matched pairs for 422 cases. Non-responders were more likely to be older and female than responders. Given the significantly increased risk profile of organ transplant patients, case-control pairs in which one member reported a history of an organ transplant were excluded (6 cases). In addition, one case-control pair had discrepant self-reported race on the questionnaire and was excluded, leaving 415 case-control pairs for analysis.

Exposure to Supplements

Patients reported if they had regularly (defined as at least once-a-week) used supplements for 3 or more months over the past 10 years from a select list of 7 supplements, which included multivitamins, vitamins A, C, D, E, polypodium leucotomos extract or grape seed extract (GSE). Information on brand, dose, frequency or duration was not ascertained. We included multivitamin use because some reports suggest that certain nutrients, such as vitamins C and E, have synergistic effects,19,23 and also as surrogate variable for health-conscious pill-taking behavior. Any subject who checked a box next to the supplement in question was considered exposed.

Covariates

Participants also answered questions on variables known to influence SCC risk including skin type, history of freckling (yes/no), eye color, natural hair color, education, family history of skin cancer, history of severe (painful and/or blistering) sunburns, regular (at least once-a-week) peak-time (between 10 am – 4 pm) sun exposure (yes/no), occupational sun exposure (yes/no), tanning bed use (yes/no), high-risk exposures including ultraviolet (UV) light treatment, burn scar, non-healing ulcers, radiation treatment, arsenic exposure, exposure to industrial chemicals (yes/no), and smoking (current vs. former/never). For respondents who reported regular peak-time sun exposure, we also ascertained the average number of hours per week, which we categorized as low (< 6 hours) or high (≥ 6 hours), as well as use of sunscreen (never/rarely vs. much/most of the time) and sun-protective clothing (never/rarely vs. much/most of the time).

Statistical Analysis

Differences in distributions of categorical covariates between cases and controls were analyzed using Pearson chi-square tests. For the matched case-control analysis, we used conditional logistic regression to estimate unadjusted and adjusted odds ratios and Wald 95% confidence intervals in 4 different models. Model 1 estimated crude, unadjusted odds ratios. Model 2 adjusted for all ascertained SCC risk factors. Model 3 adjusted for all SCC risk factors as well as exposure to each individual supplement, the use of some of which were correlated. To ensure that our multivariate analyses were not over-adjusted, we created a final model (model 4) limiting the variables to those that were associated with both exposure (individual supplements) and outcome (SCC risk) at the p<0.20 level (parsimonious model). P values were two-sided. All statistical analyses were performed using SAS, version 9.1, (SAS Institute Inc., Cary, NC).

RESULTS

The average age of participants at index date was 72.5 years ± 8.6 SD (range: 43-85 years). The majority of participants were male (n=514, 61.9%). Compared to controls, cases were more likely to have red or blond hair, blue or grey eyes, and lighter skin types. Cases were also more likely to report current smoking, a family history of skin cancer, a history of childhood freckles, routine sun exposure and severe sunburns, and exposure to other SCC high risk factors (Table 1).

Table 1
Risk Factors for Squamous Cell Carcinomas among Cases and Controls

Table 2 shows the risk of SCC in relation to individual supplement use. There was no statistically significant association of SCC risk with respect to use of vitamin A, C, D, or E in any of the 4 models, although the protective effect for multivitamin use was consistent across all models and was borderline significant in the final parsimonious model (OR: 0.71, CI: 0.51-1.00, p= 0.049).

Table 2
Supplement Use among Cases and Controls1,2

In unadjusted models, users of grape seed extract had a 69% lower odds of SCC compared to non-users (OR: 0.31, CI: 0.10-0.94, p= 0.039). In Model 2, adjusting for all ascertained SCC risk factors (hair and eye color, skin type, education, smoking, family history of skin cancer and history of freckling, sunburns, sun exposure and tanning bed use), the protective effect was more pronounced (OR: 0.22, CI: 0.06-0.87, p= 0.031). Similarly, adjusting for all SCC risk factors as well as other supplement exposures (Model 3) further strengthened the protective association (OR: 0.19, CI: 0.05-0.73, p= 0.017). In the final parsimonious model, presented in the table, grape seed extract was associated with a persistent protective effect (OR: 0.26, CI: 0.08-0.89, p=0.031). No subjects reported use of polypodium leucotomos extract.

Finally, we stratified SCCs as Bowen’s disease/in-situ SCC vs invasive SCCs; those with multiple tumors diagnosed in 2004 with both features and those not specified were excluded. Table 3 shows the risk of SCC divided into subtypes in relation to supplement use. Results for multivitamins and GSE were similar for both SCC subtypes. Use of vitamin C supplements was associated with reduced risk of in-situ disease; the confidence intervals for the other supplements were too wide to draw any conclusions.

Table 3
SCC Risk Among Supplement Users Stratified by Histologic Subtype1,2,3

DISCUSSION

Results from this case-control study show that grape seed extract use is associated with a reduction in risk of cutaneous SCC. This effect was stronger when SCC risk factors, including sun exposure variables, were included in the model. Multivitamin use showed a borderline protective effect. The other supplements that were studied (vitamins A, C, D, and E) did not reveal any associations with SCC risk in adjusted and unadjusted models. In analyses stratified by SCC histologic subtype (in-situ vs. invasive), vitamin C appeared to have a statistically significant protective effect for in-situ SCCs only. This may suggest that vitamin C may have a protective effect that is most pronounced during the early stages of carcinogenesis, or alternatively, may reflect a spurious association due to the multiple comparisons performed. Our stratified analyses were likely underpowered, as evidenced by the substantial widening in confidence intervals.

GSE has shown promise as a chemopreventative agent in other organs, such as breast, colon, and prostate,24-27 and trials are currently underway to evaluate its efficacy in these malignancies.28 However, no epidemiologic studies, to date, have evaluated oral intake of GSE and its association with cutaneous SCC risk in humans. Nevertheless, caution should be used in recommending GSE as a long-term chemopreventative supplement. Reports of side effects of GSE supplementation have included headache, dry, itchy scalp, hives, nausea and dizziness.29 More concerning are GSEs reported effects on platelet adhesion30 which may pose additional risks in patients taking anticoagulants such as warfarin, aspirin, non-steroidal anti-inflammatory drugs, or other anti-platelet agents. Also, interactions between GSE and medicines or other supplements have not been carefully studied, and there is evidence to suggest that GSE may interfere with the cytochrome p450 enzyme system.31 Although oral administration of GSE was well tolerated in people over 8 weeks of a clinical trial,32 the long-term side effects have not been adequately ascertained.

Our finding of no statistically significant association of SCC risk with individual vitamin supplements is largely consistent with those reviewed and reported in the literature.4,33,34 Reviews of published human studies investigating the role of dietary factors in the development of keratinocyte carcinomas have not revealed any consistent association between SCC risk and exposure to vitamins A, C or E.33,34 Large prospective cohort studies have also revealed no association between SCC risk and intake of vitamins A, C or E.18,35 Pre-diagnostic serum retinol levels were not associated with subsequent risk of SCC.36 Similarly, several prospective studies using serum concentration of alpha-tocepherol did not reveal any association with subsequent risk of SCC.36-38 While one double-blind placebo-controlled trial of oral vitamin A showed a reduction in risk of first new SCC in moderate-risk subjects (HR= 0.74, 95% CI 0.56-0.99, p = 0.04),20 no beneficial effects of retinol were noted in a similar trial of high risk subjects.39 Large-scale, randomized trials have not shown any association between beta carotene supplementation and SCC risk.40-42 Although some studies have suggested that specific combinations of vitamins, such as vitamin C and E have synergistic photoprotective effects,34,43,44 results of a recent trial of a combination of nutritionally appropriate doses of vitamins C, E, beta-carotene, and the minerals selenium and zinc did not reveal any difference in incidence of non-melanoma skin cancer between supplement users and placebo users.19

Strengths of this study include a large sample size (n=830) and thorough measurement of risk factors for SCC. However, no information was ascertained on dose, frequency, duration, or brand of supplement use because supplement use was not the primary exposure of interest and our study was not powered to look at this specific association. Also, although the questionnaire was modeled off of a validated instrument on supplement use and cancer risk 45, the accuracy of the survey instrument was not tested. Further limitations of this study include the possibility of recall bias, selection bias, and limitations of generalizability. Our control population came from respondents to the Member’s Health Survey and not from the Kaiser Permanente membership at large and may be prone to selection bias. However, previously published papers have reported that respondents to the MHS are representative of the KPNC population.46 Recall bias is also a potential problem for the self-reported variables, such as sun exposure history. Differential misclassification would result if the cancer diagnosis served as a stimulus for cases to recall supplement use more or less thoroughly than controls. However, the survey collected data on a variety of exposures and supplement use constituted a very small portion of the questionnaire (only one item among 24 items ascertained in questionnaire). The generalizability of our study may be limited because we only studied KPNC members, although previous studies have shown that the KPNC membership is highly representative of the surrounding region except for the tail ends of the income distribution.46,47 Although use of grape seed extract was reported by a small number of patients (n=17), nevertheless, a total of 2% of our study population reported its use, which may seem high for a non-vitamin, non-mineral supplement. However, previously published papers on supplement use within the KPNC adult population have shown that an estimated 32.7% of adult members used at least one non-vitamin, non-mineral supplement in the preceding 12 months, with use highest among whites greater than age 45, which constitutes the majority of our study sample.48

In summary, we found a protective effect of GSE use on cutaneous SCC risk. Future studies need to be performed to replicate these findings, and if confirmed, to ascertain the effects of dose or duration of GSE use on SCC risk. Given the potential toxicity of GSE, including platelet dysfunction, more studies are needed to establish the effect, determine optimal dosing and assess side effect profiles.

Capsule Summary

  • We conducted a case-control study (n=830) at Kaiser Permanente Northern California to examine the association between supplement use and cutaneous squamous cell carcinoma (SCC) risk.
  • Self-reported use of grape seed extract was associated with a decreased SCC risk.
  • Multivitamin use was associated with a borderline significant reduction in SCC risk.
  • Use of vitamins A, C, D and E was not associated with SCC risk.

Acknowledgments

Funding Sources: This study was supported by the National Institute of Arthritis Musculoskeletal and Skin Diseases (K23 AR 051037 to MA, K24 AR 052667 to MC) and by the National Cancer Institute (R01 CA 098838 to GF, K05CA154337 to EW).

Abbreviations

GSE
grape seed extract
NSAIDs
non-steroidal anti-inflammatory drugs
KPNC
Kaiser Permanente Northern California
MHS
Member Health Survey
SCC
squamous cell carcinoma
UV
ultraviolet

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of Interest Disclosure: The authors have no conflict of interest to disclose.

References

(1) Fryer MJ. Evidence for the photoprotective effects of vitamin E. Photochem Photobiol. 1993;58:304–312. [PubMed]
(2) Steenvoorden DP, van Henegouwen GM. The use of endogenous antioxidants to improve photoprotection. J Photochem Photobiol B. 1997;41:1–10. [PubMed]
(3) Reichrath J, Rafi L, Rech M, et al. Analysis of the vitamin D system in cutaneous squamous cell carcinomas. J Cutan Pathol. 2004;31:224–231. [PubMed]
(4) Wright TI, Spencer JM, Flowers FP. Chemoprevention of nonmelanoma skin cancer. J Am Acad Dermatol. 2006;54:933–946. [PubMed]
(5) Middelkamp-Hup MA, Pathak MA, Parrado C, et al. Oral Polypodium leucotomos extract decreases ultraviolet-induced damage of human skin. J Am Acad Dermatol. 2004;51:910–918. [PubMed]
(6) Katiyar SK. Grape seed proanthocyanidines and skin cancer prevention: inhibition of oxidative stress and protection of immune system. Mol Nutr Food Res. 2008;52(Suppl 1):S71–S76. [PMC free article] [PubMed]
(7) Bomser JA, Singletary KW, Wallig MA, Smith MA. Inhibition of TPA-induced tumor promotion in CD-1 mouse epidermis by a polyphenolic fraction from grape seeds. Cancer Lett. 1999;135:151–157. [PubMed]
(8) Zhao J, Wang J, Chen Y, Agarwal R. Anti-tumor-promoting activity of a polyphenolic fraction isolated from grape seeds in the mouse skin two-stage initiation-promotion protocol and identification of procyanidin B5-3′-gallate as the most effective antioxidant constituent. Carcinogenesis. 1999;20:1737–1745. [PubMed]
(9) Kowalczyk MC, Walaszek Z, Kowalczyk P, Kinjo T, Hanausek M, Slaga TJ. Differential effects of several phytochemicals and their derivatives on murine keratinocytes in vitro and in vivo: implications for skin cancer prevention. Carcinogenesis. 2009;30:1008–1015. [PMC free article] [PubMed]
(10) Meeran SM, Katiyar SK. Grape seed proanthocyanidins promote apoptosis in human epidermoid carcinoma A431 cells through alterations in Cdki-Cdk-cyclin cascade, and caspase-3 activation via loss of mitochondrial membrane potential. Exp Dermatol. 2007;16:405–415. [PubMed]
(11) Mittal A, Elmets CA, Katiyar SK. Dietary feeding of proanthocyanidins from grape seeds prevents photocarcinogenesis in SKH-1 hairless mice: relationship to decreased fat and lipid peroxidation. Carcinogenesis. 2003;24:1379–1388. [PubMed]
(12) Joshi SS, Kuszynski CA, Bagchi D. The cellular and molecular basis of health benefits of grape seed proanthocyanidin extract. Curr Pharm Biotechnol. 2001;2:187–200. [PubMed]
(13) Bagchi D, Bagchi M, Stohs S, Ray SD, Sen CK, Preuss HG. Cellular protection with proanthocyanidins derived from grape seeds. Ann N Y Acad Sci. 2002;957:260–270. (12) Werninghaus K, Meydani M, Bhawan J, Margolis R, Blumberg JB, Gilchrest BA. Evaluation of the photoprotective effect of oral vitamin E supplementation. Arch Dermatol. 1994;130:1257-1261. [PubMed]
(14) Pauling L, Willoughby R, Reynolds R, Blaisdell BE, Lawson S. Incidence of squamous cell carcinoma in hairless mice irradiated with ultraviolet light in relation to intake of ascorbic acid (vitamin C) and of D, L-alpha-tocopheryl acetate (vitamin E) Int J Vitam Nutr Res Suppl. 1982;23:53–82. [PubMed]
(15) Burke KE, Clive J, Combs GF, Jr., Commisso J, Keen CL, Nakamura RM. Effects of topical and oral vitamin E on pigmentation and skin cancer induced by ultraviolet irradiation in Skh:2 hairless mice. Nutr Cancer. 2000;38:87–97. [PubMed]
(16) Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS. 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res. 1999;59:2644–2649. [PubMed]
(17) Werninghaus K, Meydani M, Bhawan J, Margolis R, Blumberg JB, Gilchrest BA. Evaluation of the photoprotective effect of oral vitamin E supplementation. Arch Dermatol. 1994;130:1257–1261. [PubMed]
(18) Fung TT, Spiegelman D, Egan KM, Giovannucci E, Hunter DJ, Willett WC. Vitamin and carotenoid intake and risk of squamous cell carcinoma of the skin. Int J Cancer. 2003;103:110–115. [PubMed]
(19) Hercberg S, Ezzedine K, Guinot C, et al. Antioxidant supplementation increases the risk of skin cancers in women but not in men. J Nutr. 2007;137:2098–2105. [PubMed]
(20) Moon TE, Levine N, Cartmel B, et al. Southwest Skin Cancer Prevention Study Group Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Cancer Epidemiol Biomarkers Prev. 1997;6:949–956. [PubMed]
(21) Reichrath J, Rafi L, Rech M, et al. Analysis of the vitamin D system in cutaneous squamous cell carcinomas. J Cutan Pathol. 2004;31:224–231. [PubMed]
(22) Asgari MM, Chren MM, Warton MM. Association of Use of Nonsteroidal Anti-inflammatory Drugs and Cutaneous Squamous Cell Carcinoma. Arch.Dermatol. 2009 In press.
(23) Treloar V. Chemoprevention and vitamin E. J Am Acad Dermatol. 2007;57:903. [PubMed]
(24) Mantena SK, Baliga MS, Katiyar SK. Grape seed proanthocyanidins induce apoptosis and inhibit metastasis of highly metastatic breast carcinoma cells. Carcinogenesis. 2006;27:1682–1691. [PubMed]
(25) Kaur M, Agarwal C, Agarwal R. Anticancer and cancer chemopreventive potential of grape seed extract and other grape-based products. J Nutr. 2009;139:1806S–1812S. [PubMed]
(26) Kaur M, Agarwal R, Agarwal C. Grape seed extract induces anoikis and caspase-mediated apoptosis in human prostate carcinoma LNCaP cells: possible role of ataxia telangiectasia mutated-p53 activation. Mol Cancer Ther. 2006;5:1265–1274. [PubMed]
(27) Raina K, Singh RP, Agarwal R, Agarwal C. Oral grape seed extract inhibits prostate tumor growth and progression in TRAMP mice. Cancer Res. 2007;67:5976–5982. [PubMed]
(28) National Institutes of Health [Accessed November 30, 2009];Research Portfolio Online Reporting Tool. Available at: http://projectreporter.nih.gov/reporter.cfm.
(29) National Institutes of Health. National Center for Complimentary and Alternative Medicine Herbs at a Glance:Grape Seed Extract. Available at: http://nccam.nih.gov/health/grapeseed#cautions. Accessed November 30, 2009.
(30) Shanmuganayagam D, Beahm MR, Osman HE, Krueger CG, Reed JD, Folts JD. Grape seed and grape skin extracts elicit a greater antiplatelet effect when used in combination than when used individually in dogs and humans. J Nutr. 2002;132:3592–3598. [PubMed]
(31) Etheridge AS, Black SR, Patel PR, So J, Mathews JM. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med. 2007;73:731–741. [PubMed]
(32) Ray S, Bagchi D, Lim PM, et al. Acute and long-term safety evaluation of a novel IH636 grape seed proanthocyanidin extract. Res Commun Mol Pathol Pharmacol. 2001;109:165–197. [PubMed]
(33) McNaughton SA, Marks GC, Green AC. Role of dietary factors in the development of basal cell cancer and squamous cell cancer of the skin. Cancer Epidemiol Biomarkers Prev. 2005;14:1596–1607. [PubMed]
(34) Bialy TL, Rothe MJ, Grant-Kels JM. Dietary factors in the prevention and treatment of nonmelanoma skin cancer and melanoma. Dermatol Surg. 2002;28:1143–1152. [PubMed]
(35) Heinen MM, Hughes MC, Ibiebele TI, Marks GC, Green AC, van der Pols JC. Intake of antioxidant nutrients and the risk of skin cancer. Eur J Cancer. 2007;43:2707–2716. [PubMed]
(36) Karagas MR, Greenberg ER, Nierenberg D, et al. Risk of squamous cell carcinoma of the skin in relation to plasma selenium, alpha-tocopherol, beta-carotene, and retinol: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 1997;6:25–29. [PubMed]
(37) Dorgan JF, Boakye NA, Fears TR, et al. Serum carotenoids and alpha-tocopherol and risk of nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:1276–1282. [PubMed]
(38) van der Pols JC, Heinen MM, Hughes MC, Ibiebele TI, Marks GC, Green AC. Serum antioxidants and skin cancer risk: an 8-year community-based follow-up study. Cancer Epidemiol Biomarkers Prev. 2009;18:1167–1173. [PubMed]
(39) Levine N, Moon TE, Cartmel B, et al. Southwest Skin Cancer Prevention Study Group Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Cancer Epidemiol Biomarkers Prev. 1997;6:957–961. [PubMed]
(40) Frieling UM, Schaumberg DA, Kupper TS, Muntwyler J, Hennekens CH. A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the physician’s health study. Arch Dermatol. 2000;136:179–184. [PubMed]
(41) Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet. 1999;354:723–729. [PubMed]
(42) Greenberg ER, Baron JA, Stukel TA, et al. The Skin Cancer Prevention Study Group A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. N Engl J Med. 1990;323:789–795. [PubMed]
(43) Eberlein-Konig B, Placzek M, Przybilla B. Protective effect against sunburn of combined systemic ascorbic acid (vitamin C) and d-alpha-tocopherol (vitamin E) J Am Acad Dermatol. 1998;38:45–48. [PubMed]
(44) Fuchs J, Kern H. Modulation of UV-light-induced skin inflammation by D-alpha-tocopherol and L-ascorbic acid: a clinical study using solar simulated radiation. Free Radic Biol Med. 1998;25:1006–1012. [PubMed]
(45) Satia-Abouta J, Patterson RE, King IB, Stratton KL, Thornquist MD, Shattuck AL, Kristal AK, Potter JD, White E. Reliability and validity of self-report of vitamin and mineral supplement use in the VITamins And Lifestyle (VITAL) Study. Am J Epidemiol. 2003;157:944–54. [PubMed]
(46) Gordon NP. How Does the Adult Kaiser Permanente Membership in Northern California Compare with the Larger Community? Kaiser Permanente Division of Research; Oakland, CA: [Accessed November 30, 2009]. 2006. Available at: http://www-dor.kaiser.org/dor/mhsnet/public/pdf_supplemental_public/comparison_kaiser_vs_nonKaiser_adults_kpnc.pdf.
(47) Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health. 1992;82:703–710. [PubMed]
(48) Schaffer DM, Gordon NP, Jensen CD, Avins AL. Nonvitamin, nonmineral supplement use over a 12-month period by adult members of a large health maintenance organization. J Am Diet Assoc. 2003;103:1500–1505. [PubMed]